Parkland resident Matheus Kunzler Maldaner has certainly made his parents proud and, given a few more years, is likely to ...
MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback